Trial Profile
A Randomized, Double-Blind Phase 2/3 Study of Relatlimab Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Metastatic or Unresectable Melanoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II/III
Latest Information Update: 19 Apr 2024
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Nivolumab/relatlimab (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma
- Focus Registrational; Therapeutic Use
- Acronyms RELATIVITY-047
- Sponsors Bristol-Myers Squibb
- 24 Oct 2023 Results of Post hoc analyses exploring the efficacy of NIVO + RELA vs NIVO according to baseline (BL) sites of metastasis (mets) and the time to development of CNS mets , presented at the 48th European Society for Medical Oncology Congress
- 24 Oct 2023 Results evaluating surrogate endpoints for overall survival were presented at the 48th European Society for Medical Oncology Congress.
- 24 Oct 2023 Results of exploratory biomarker analysis to elucidate mechanisms underlying NIVO+RELA activity and identify patients more likely to derive benefit from the combination presented at the 48th European Society for Medical Oncology Congress